awmsg logo



darunavir (Prezista®)


Reference No. 100

Publication date:
03/02/2010


Appraisal information

darunavir (Prezista®) film-coated tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 11/11/2009
AWMSG meeting date: 16/12/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2009
Ministerial ratification: 27/01/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Darunavir (Prezista®) co-administered with low dose ritonavir is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus (HIV)-1 infection in treatment naive patients. AWMSG is of the opinion that darunavir (Prezista®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download